首页|疏肝健脾方联合左甲状腺素钠治疗桥本甲状腺炎合并甲状腺功能减退的疗效

疏肝健脾方联合左甲状腺素钠治疗桥本甲状腺炎合并甲状腺功能减退的疗效

扫码查看
目的 分析疏肝健脾方联合左甲状腺素钠治疗桥本甲状腺炎合并甲状腺功能减退(简称甲减)患者的效果。方法 将河南省郑州市第九人民医院内分泌代谢科2022年1月至2023年10月收治的80例桥本甲状腺炎合并甲减患者按照治疗方法分为对照组(40例)和研究组(40例)。对照组患者进行左甲状腺素钠治疗,研究组患者进行疏肝健脾方联合左甲状腺素钠治疗,治疗时间为3个月。对2组患者治疗后效果,治疗前后血清炎症因子指标[肿瘤坏死因子-α(TNF-α)、白细胞介素-6(IL-6)、白细胞介素-12(IL-12)、干扰素-γ(IFN-γ)]、甲状腺相关指标[促甲状腺激素(TSH)、游离三碘甲状腺原氨酸(FT3)、游离四碘甲状腺原氨酸(FT4)]、淋巴细胞亚群指标(CD4+、CD8+、CD4+/CD8+、CD3+)及治疗过程中不良反应进行比较。结果 经过临床治疗发现,对照组、研究组的治疗有效患者分别为32例(80。0%)、39例(97。5%),研究组较对照组高(P<0。05);治疗后相较于治疗前2组患者血清TNF-α、IL-6、IL-12、IFN-γ、TSH水平及CD8+降低,相较于对照组,研究组更低(P<0。05),FT3、FT4水平及CD4+、CD3+、CD4+/CD8+升高,相较于对照组,研究组更高(P<0。05)。结论 桥本甲状腺炎合并甲减患者采用疏肝健脾方联合左甲状腺素钠治疗可提升疗效,减轻体内炎症因子的分泌,改善甲状腺功能,调节患者T细胞亚群,安全性较好。
Effects of Liver-Sparing and Spleen-Strengthening Formula combined with levothyroxine sodium in the treatment of Hashimoto's thyroiditis combined with hypothyroidism
Objective To analyze the effects of Liver-Sparing and Spleen-Strengthening Formula com-bined with levothyroxine sodium on the treatment of patients with Hashimoto's thyroiditis combined with hypothy-roidism.Methods A total of 80 patients with Hashimoto's thyroiditis complicated with hypothyroidism admitted to the Endocrinology and Metabolism Department of Zhengzhou Ninth People's Hospital from January 2022 to October 2023 were divided into a control group (40 cases) and a study group (40 cases) according to treatment methods.The patients in the control group were treated with levothyroxine sodium,and the patients in the study group were treated with Liver-Sparing and Spleen-Strengthening Formula combined with levothyroxine sodium,and the treatment time was 3 months.Compare the treatment effects,serum inflammatory factors[tumor necrosis factor-alpha (TNF-α),interleukin-6 (IL-6),interleukin-12 (IL-12),interferon-gamma (IFN-γ)],thyroid related factors[thyroid-stimulating hormone (TSH),free tri-iodothyronine (FT3),free tetra-iodothyronine (FT4)],lymphocyte subset factors (CD4+,CD8+,CD4+/CD8+,CD3+),and adverse reactions during the treatment process between two groups of patients before and after treatment.Results After treatment,there were 32 effective patients (80.0%) in the control group and 39 effective patients (97.5%) in the study group,and the study group was more effective than the control group.Compared with before treatment,the levels of serum TNF-α,IL-6,IL-12,IFN-γ,TSH,and CD8+of patients in both groups decreased after treatment;Compared to the control group,the above indicators in the study group were lower.Compared with before treatment,the levels of serum FT3 and FT4,as well as CD4+,CD3+,CD4+/CD8+increased in both groups of patients after treatment;Compared to the control group,the above indica-tors in the study group were higher (P<0.05).Conclusion The treatment of Hashimoto's thyroiditis combined with hypothyroidism with Liver-Sparing and Spleen-Strengthening Formula combined with levothyroxine sodium can further enhance the therapeutic efficacy,alleviate the secretion of inflammatory factors in the body,improve the function of the thyroid gland,and regulate the subpopulation of the patient's T-lymphocytes,with a better safety.

Hashimoto diseaseHypothyroidismDispersing stagnated liver Qi and Strengthening spleenThyroxineLymphocytes

贾琳、申小娜、田琳

展开 >

郑州市第九人民医院内分泌代谢科,河南郑州 450000

桥本病 甲状腺功能减退症 疏肝健脾 甲状腺素 淋巴细胞

2024

中国药物与临床
中国医院协会

中国药物与临床

影响因子:0.846
ISSN:1671-2560
年,卷(期):2024.24(23)